Harrison.ai, a global leader in AI-powered medical diagnostic support and workflow solutions, has announced its accelerated expansion into the United States. This strategic move is backed by a $112 million Series C funding round, marking one of the largest capital raises in the medical AI sector over the past year.
Funding to Drive Global Expansion and Product Innovation
The latest investment round will not only facilitate Harrison.ai’s entry into the US market but also fuel its product development roadmap and continued growth across the UK, EMEA, and APAC regions. The Series C funding was co-led by Aware Super, ECP, and existing investor Horizons Ventures. New investors, including Australia’s National Reconstruction Fund Corporation (NRFC), Ord Minnett, and Wollemi Capital Group, also participated in the round, alongside established backers such as Blackbird Ventures and Alpha JWC Ventures. To date, Harrison.ai has raised over US$240 million in capital.
Revolutionizing Medical Diagnostics with AI
Harrison.ai has emerged as a pioneering force in AI-driven healthcare solutions, particularly in radiology and pathology. Its technology assists clinicians in detecting signs of cancer and other critical illnesses earlier, enhancing treatment decisions and patient outcomes. By leveraging AI to analyze CT scans, X-rays, and pathology slides, the company provides clinicians with powerful tools to diagnose conditions faster and more accurately.
The company’s radiology solution, Annalise.ai, has seen widespread adoption, with its technology now supporting over 1,000 healthcare facilities globally. Each year, more than six million patients benefit from Harrison.ai’s solutions. In Australia, Annalise.ai is accessible to 1 in 2 radiologists and is widely used across public hospitals. In the United Kingdom, the company processes scans for more than 45 NHS Trusts and over 131 public hospitals, covering approximately 35% of chest X-ray volume in England. Additionally, its technology powers all CT Brain scans in Hong Kong’s public accident and emergency (A&E) systems and has been recently adopted by the Danish public healthcare system.
Expanding into the US Market
As part of its ambitious global expansion, Harrison.ai is establishing a North American presence in Boston. This move aims to strengthen the company’s US operations, expand its customer base, and enhance collaboration with leading healthcare institutions. Harrison.ai has already made significant strides in the US regulatory landscape, securing 12 FDA clearances. Notably, one of its CT Brain algorithms has received FDA Breakthrough Device Designation and Medicare reimbursement through the New Technology Add-on Payment (NTAP), further validating the company’s impact and credibility in the sector.
“The US represents an enormous opportunity for AI-driven healthcare innovation,” said Dimitry Tran, Co-Founder and COO of Harrison.ai. “With this investment, we are poised to accelerate our commercialization efforts, bringing our cutting-edge diagnostic AI solutions to more healthcare providers and patients worldwide.”
Advancing AI-Driven Healthcare Solutions
Harrison.ai’s continued focus on AI in radiology and pathology has positioned it at the forefront of medical AI advancements. With an emphasis on early disease detection and clinical workflow optimization, the company is addressing key challenges in global healthcare, including clinician shortages and increasing diagnostic complexity.
Through strategic partnerships with hospitals and healthcare organizations, Harrison.ai is streamlining medical imaging interpretation and pathology workflows, significantly reducing time to diagnosis and improving patient outcomes. By integrating AI with existing healthcare infrastructure, the company is enhancing clinical efficiency while maintaining high diagnostic accuracy standards.
Impact on the Future of Healthcare
The expansion into the United States, combined with the latest capital infusion, is expected to further solidify Harrison.ai’s position as a leader in AI-driven medical diagnostics. As AI technology continues to evolve, its role in healthcare is becoming increasingly critical, particularly in improving access to timely and accurate medical diagnoses.
Industry experts view Harrison.ai’s rapid growth as indicative of a broader trend where AI is transforming traditional healthcare models. By automating and optimizing diagnostic processes, AI-powered tools can help address systemic challenges, such as overburdened healthcare systems and disparities in medical expertise across regions.
Challenges and Competitive Landscape
Despite its strong market position, Harrison.ai faces competition from other AI-driven healthtech firms, particularly in the US market, where regulatory compliance and integration with existing healthcare systems pose challenges. However, the company’s track record of successful deployments across various geographies, along with its regulatory approvals, provides a strong foundation for its expansion.
The ability to gain widespread adoption will depend on factors such as reimbursement policies, clinical validation, and the company’s ability to forge partnerships with major healthcare providers. Harrison.ai’s focus on securing FDA clearances and Medicare reimbursement options is a strategic step toward ensuring its solutions are both accessible and scalable in the US healthcare landscape.
Looking Ahead
With a solid financial backing and an expanding global footprint, Harrison.ai is set to redefine how AI is used in medical diagnostics. Its solutions are bridging the gap between artificial intelligence and clinical practice, offering a glimpse into the future of AI-assisted healthcare.
As Harrison.ai continues to push the boundaries of medical AI, its commitment to improving diagnostic accuracy, reducing clinician workload, and enhancing patient care remains at the core of its mission. The company’s expansion into the US is not just a business move—it represents a significant step forward in the broader adoption of AI-driven healthcare solutions worldwide.
Conclusion
Harrison.ai’s accelerated US expansion, backed by $112 million in Series C funding, is a game-changer for AI-driven medical diagnostics. With a strong presence already established in Australia, the UK, and other global markets, the company is now poised to revolutionize the US healthcare sector with its cutting-edge AI solutions.
By leveraging artificial intelligence to assist clinicians in radiology and pathology, Harrison.ai is addressing some of the most pressing challenges in modern medicine. As the company continues to grow and innovate, its impact on global healthcare is expected to be profound, setting new standards for AI-powered diagnostics and workflow optimization.